You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨藥明生物(2269.HK)升逾5%破頂 市值超3900億港元
格隆匯 12-28 10:44
格隆匯12月28日丨藥明生物(2269.HK)續升5.3%,盤中高見96.65港元再創新高,年內股價已漲逾3倍,暫成交3.74港元,總市值3931億港元。公司間接全資附屬公司WuXi Biologics Germany與獨立第三方Bayer於2020年12月21日訂立資產購買協議。預計該兩座生產工廠將於2021年投入生產,為集團歐洲生產供應鏈提供有力支持。中銀國際升藥明生物目標價至105港元,維持買入;瑞信日期升藥明生物目標價至107港元,評級“跑贏大市”。指出藥明生物預期在疫情影響下,2021財年銷售額將按年增長50%,2022財年則增長40%至50%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account